Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | CDC42 | P60953 | 1/20 | 0.57 |
| ▸ | RAC1 | P63000 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1448872 | 0.99 | PTGS2 (0.62) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL7101761 | 0.95 | PTGS2 (0.63) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL13592731 | 0.92 | TDP1 (0.69) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL554679 | 0.91 | TDP1 (0.55) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL17858883 | 0.90 | PTGS2 (0.66) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL10649402 | 0.90 | PTGS2 (0.66) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL10729842 | 0.89 | PTGS2 (0.62) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL9243075 | 0.89 | PTGS2 (0.62) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL3106087 | 0.89 | PTGS2 (0.62) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 | |
| SCHEMBL11718787 | 0.89 | PTGS2 (0.62) | PTGS2TDP1L3MBTL1PTGS1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385824-A2 | COMPOUNDS CO-INDUCING CHOLINERGIC UP-REGULATION AND INFLAMMATION DOWN-REGULATION AND USES THEREOF | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2004-02-04 | — | — | EP | disclosed |
| US-20020160988-A1 | Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2002-10-31 | — | — | US | disclosed |
| WO-2002065977-A2 | COMPOUNDS CO-INDUCING CHOLINERGIC UP-REGULATION AND INFLAMMATION DOWN-REGULATION AND USES THEREOF | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160988-A1 | Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof | CHAT, ACHE, CHRNB2 | PTGS2 65/4885TDP1 2004/4885L3MBTL1 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.